// App-Quantinova.ai

TPS2103 : A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment response after WBRT sorafenib.

Researchers

Presenter

  • Aki Morikawa

Principal Investigators

  • Komal L. Jhaveri

  • Sujata Patil

  • Kathryn Beal

  • Deirdre A. Neville

  • Fung Ming Mak

  • Bolorsukh Gansukh

  • Humm L. John

  • Andrei Holodny

  • Heiko Schder

  • Andrew David Seidman

  • Melanie Chen

  • Edward McDonnell

Medical Centers

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, NYNew York University School of Medicine, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Sorafenib

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01724606

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved